Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Assets (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Assets for 16 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 65.71% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 65.71% year-over-year, with the annual reading at $1.6 billion for FY2025, 65.71% up from the prior year.
  • Assets hit $1.6 billion in Q4 2025 for Ligand Pharmaceuticals, up from $1.5 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.6 billion in Q4 2025 to a low of $758.1 million in Q2 2023.
  • Historically, Assets has averaged $1.0 billion across 5 years, with a median of $951.7 million in 2024.
  • Biggest five-year swings in Assets: tumbled 41.22% in 2022 and later soared 65.71% in 2025.
  • Year by year, Assets stood at $1.3 billion in 2021, then crashed by 41.22% to $762.7 million in 2022, then rose by 3.22% to $787.2 million in 2023, then grew by 19.63% to $941.8 million in 2024, then skyrocketed by 65.71% to $1.6 billion in 2025.
  • Business Quant data shows Assets for LGNDZ at $1.6 billion in Q4 2025, $1.5 billion in Q3 2025, and $948.6 million in Q2 2025.